PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'School of Public Health, Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia. Electronic address: colleen.lau@uq.edu.au.\', \'School of Public Health, Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.\', \'School of Chemistry and Molecular Biosciences, Faculty of Science, The University of Queensland, Brisbane, Queensland, Australia.\', \'School of Medicine and Public Health, University of Newcastle, Callaghan, NSW, Australia; Calvary Mater Newcastle Hospital, Waratah, NSW, Australia; NSW Health Pathology John Hunter Hospital, New Lambton Heights, NSW, Australia.\', \'St Kilda Medical Group, St Kilda, Victoria, Australia.\', \'School of Mathematical Sciences, Faculty of Science, Queensland University of Technology, Brisbane, Queensland, Australia.\', \'Discipline of General Practice, College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia; Scientific Advisory Committee, Immunisation Coalition, Melbourne, Victoria, Australia.\']
?:citedBy
  • -1
?:creator
?:doi
  • S0264-410X(21)01428-610.1016/j.vaccine.2021.10.079
?:doi
?:hasPublicationType
?:journal
  • Vaccine
is ?:pmid of
?:pmid
?:pmid
  • 34810000
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.863
?:rankingScore_hIndex
  • 159
?:title
  • Risk-benefit analysis of the AstraZeneca COVID-19 vaccine in Australia using a Bayesian network modelling framework.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all